Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma
Nirupama Kasturi1★, Tharini Senthamizh1, Hanuman Srinivas Bheemanathi1, K. Ramesh Babu2★ Corresponding author
- 1Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
- 2Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
CORRESPONDENCE
Nirupama Kasturi
Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry - 605 006, India.
Received: 03-11-2018; Revised: 23-12-2018; Accepted: 01-04-2019.
Volume 10, Issue 1 · pp. 42–44 · PUBLISHED 2019 · DOI: 10.4103/jpp.JPP_123_18
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
A 45-year-old male presented with a pyogenic granuloma of the bulbar conjunctiva of the left eye following a stick injury. It was a benign friable, hyperplastic, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. The differential diagnosis includes squamous papillomas, hemangiomas, suture granulomas, and ocular surface tumors, such as squamous cell carcinoma and amelanotic melanoma. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites, and plaque irradiation has been described. We present a case of recurrent pyogenic granuloma successfully treated with two subconjunctival bevacizumab injections. The patient developed three recurrences after excision at a peripheral hospital after which he was successfully treated with excision and adjuvant subconjunctival bevacizumab 2.5 mg/0.1 ml injection. This case highlights the novel use of bevacizumab for recurrent pyogenic granuloma.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kasturi, N., Senthamizh, T., Bheemanathi, H. S., & Babu, K. R. (2019). Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma. Journal of Pharmacology and Pharmacotherapeutics, 10(1), 42–44. https://doi.org/10.4103/jpp.JPP_123_18
